Prion Protein (PRNP)

Prion Protein (PRNP)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Cellular Prion Protein (PrP)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[PRNP](/genes/prnp)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P04156" target="_blank">P04156</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>33-35 kDa (253 amino acids)</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Cell membrane ( GPI-anchored), cytoplasm, nucleus</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Prion protein family</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>20p13</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Creutzfeldt-Jakob Disease](/diseases/prion-diseases), Fatal Familial Insomnia, Kuru, Bovine Spongiform Encephalopathy</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Cellular Prion Protein (PRNP)

Pathway / Mechanism Diagram

Introduction

Prion Protein (PRNP)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Cellular Prion Protein (PrP)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[PRNP](/genes/prnp)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P04156" target="_blank">P04156</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>33-35 kDa (253 amino acids)</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Cell membrane ( GPI-anchored), cytoplasm, nucleus</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Prion protein family</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>20p13</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Creutzfeldt-Jakob Disease](/diseases/prion-diseases), Fatal Familial Insomnia, Kuru, Bovine Spongiform Encephalopathy</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Cellular Prion Protein (PRNP)

Pathway / Mechanism Diagram

Introduction

The cellular prion protein (PrP), encoded by the [PRNP](/genes/prnp) gene, is a GPI-anchored glycoprotein expressed predominantly in the central nervous system. While its precise physiological function remains incompletely understood, PrP is best known for its central role in prion diseases—a unique class of fatal neurodegenerative disorders caused by the pathological conversion of the normal cellular isoform (PrP^C) into an infectious, self-propagating isoform (PrP^Sc) [@Linden2024][@Watzlawik2023].

Prion diseases include [Creutzfeldt-Jakob disease](/diseases/prion-diseases) (CJD), fatal familial insomnia (FFI), kuru, and variant CJD linked to bovine spongiform encephalopathy (BSE). These disorders represent a paradigm in neurodegeneration where a single protein can undergo a conformational transformation that triggers progressive neurotoxicity and spongiform changes in the brain. The discovery that prion diseases can be infectious, inherited, and sporadic has fundamentally transformed our understanding of protein misfolding in neurodegeneration [@Prusiner2015][@Caughey2023].

Beyond its role in prion diseases, PrP has been implicated in other neurodegenerative conditions, including [Alzheimer's disease](/diseases/alzheimers-disease), where interactions between PrP and amyloid-beta may influence disease pathogenesis [@Watts2014].

Structure and Biochemistry

Protein Architecture

PrP is a 253-amino acid protein with a distinctive domain structure [@Watzlawik2023][@Zanusso2016]:

Conformational States

The key property of PrP is its ability to adopt distinct conformational states:

• PrP^C (cellular): Predominantly α-helical, soluble, protease-sensitive, and non-infectious
• PrP^Sc (scrapie): Enriched in β-sheet structure, insoluble, partially protease-resistant, and capable of self-propagation
• PrP^C can be converted to PrP^Sc through interaction with existing PrP^Sc seeds, a process central to prion disease pathogenesis

Post-Translational Modifications

PrP undergoes several important modifications:

• N-linked glycosylation at Asn181 and Asn197: Affects folding, trafficking, and disease susceptibility
• Disulfide bond between Cys179 and Cys214: Stabilizes the C-terminal globular domain
• GPI anchoring: Targets PrP to lipid rafts in the plasma membrane
• Copper binding: The octapeptide repeats can coordinate Cu²⁺ ions with varying affinity

Normal Physiological Function

Despite extensive research, the physiological functions of PrP remain incompletely defined. Several lines of evidence support important roles in:

Synaptic Function

PrP is highly expressed at synapses, particularly in the [hippocampus](/brain-regions/hippocampus) and [cerebellum](/brain-regions/cerebellum). Studies suggest it participates in [@Purro2012][@Bellinger2015]:

• Synaptic plasticity and long-term potentiation
• Synaptic vesicle trafficking and neurotransmitter release
• Maintenance of synaptic structure

Copper Homeostasis

The octapeptide repeat region binds copper ions with high affinity, suggesting a role in:

• Cellular copper uptake and distribution
• Antioxidant defense through copper-dependent enzymes
• Modulation of synaptic copper signaling

Cell Signaling

PrP interacts with multiple cell surface proteins and can:

• Activate signaling cascades through various receptors
• Interact with neural cell adhesion molecules
• Modulate neuroprotective pathways

Neuroprotection

PrP may provide neuroprotective effects through:

• Anti-apoptotic signaling
• Protection against oxidative stress
• Regulation of autophagy

Prion Diseases

Disease Spectrum

Prion diseases can be acquired through infection, inherited through mutations in PRNP, or arise sporadically [@Belay1999][@Geschwind2015]:

Pathogenesis

PrP^Sc accumulation in the brain leads to:

• Spongiform degeneration: Vacuolation of brain tissue
• Neuronal loss: Progressive death of neurons
• Gliosis: Activation of astrocytes and microglia
• Amyloid plaque formation: In some variants

Genetic Susceptibility

Polymorphisms at codon 129 of PRNP (methionine or valine) strongly influence disease susceptibility and phenotype:

• 129M/M: Predisposes to vCJD and certain CJD subtypes
• 129V/V: Associated with longer incubation times
• Heterozygosity may provide some protection

Relationship to Alzheimer's Disease

Interesting connections between PrP and AD have emerged [@Watts2014]:

PrP as an Aβ Receptor

PrP can bind amyloid-beta peptides and may function as a receptor mediating Aβ-induced synaptic dysfunction. This interaction may:

• Facilitate Aβ toxicity at synapses
• Activate downstream signaling pathways
• Contribute to early synaptic impairment in AD

Shared Mechanisms

Both prion diseases and AD involve:

• Protein misfolding and aggregation
• Synaptic loss
• Progressive neurodegeneration
• spreading through brain networks

Therapeutic Implications

Understanding the intersection of PrP and AD pathology may reveal novel therapeutic targets for both conditions.

Molecular Mechanisms of PrP-Aβ Interaction

Binding Sites:

• The Aβ binding region on PrP is located in the N-terminal domain
• Specific amino acids (including glutamine and asparagine residues) facilitate Aβ binding
• The interaction is thought to be largely hydrophobic with some electrostatic components

• PrP-Aβ binding activates Fyn kinase
• Leads to NMDA receptor phosphorylation
• Results in excitotoxic calcium influx
• Triggers downstream apoptotic pathways

• PrP mediates Aβ-induced synaptic spine loss
• Impairs long-term potentiation (LTP)
• Disrupts synaptic plasticity mechanisms
• Contributes to early cognitive deficits

PrP in Other Neurodegenerative Diseases

Parkinson's Disease:

• PrP may interact with alpha-synuclein
• Potential role in Lewy body formation
• Possible influence on dopaminergic neuron survival

• PrP expression altered in HD models
• May interact with mutant huntingtin
• Potential contribution to synaptic dysfunction

• PrP implicated in TDP-43 proteinopathy
• Potential role in motor neuron vulnerability
• May influence disease progression

PrP and Neuroinflammation

Microglial Activation:

• PrP can be released from neurons in exosomes
• Extracellular PrP may activate microglia
• Contributes to chronic neuroinflammation
• Creates feedback loop promoting neurodegeneration

• PrP influences cytokine production
• Modulates inflammatory responses
• May both promote and suppress inflammation depending on context

• PrP affects BBB integrity
• Dysregulation may allow peripheral immune cell entry
• Contributes to neuroinflammatory processes

Cellular PrP Functions

Protein Quality Control:

• PrP interacts with cellular quality control machinery
• May help target misfolded proteins for degradation
• Loss of PrP function may impair protein clearance

• Copper binding is well-characterized
• PrP may also bind other metal ions (zinc, iron)
• Metal dyshomeostasis is implicated in multiple neurodegenerative diseases

• PrP functions as a cell adhesion molecule
• Mediates cell-cell interactions at synapses
• Influences neuronal connectivity during development

PrP in Aging and Cellular Senescence

Age-Related Changes:

• PrP expression changes with age
• Oxidative modifications accumulate
• May contribute to age-related neuronal vulnerability

• PrP may influence cellular senescence pathways
• Senescent neurons show altered PrP expression
• Could contribute to age-related neurodegeneration

PrP Spread and Propagation

Prion-Like Mechanisms:

• Aβ and tau can propagate via prion-like mechanisms
• PrP may facilitate this spread
• Template-driven misfolding in other proteins

• Neurons with high PrP expression are more vulnerable
• Different brain regions show varying susceptibility
• Regional PrP levels influence disease patterns

Biomarkers and Diagnostic Applications

Fluid Biomarkers:

• CSF PrP levels as potential biomarker
• 14-3-3 protein in CSF for CJD diagnosis
• Tau and neurofilament light chain measurements

• PET ligands for PrP aggregates
• MRI for detecting spongiform changes
• Diffusion tensor imaging for connectivity changes

• PRNP polymorphisms modify disease risk
• Codon 129 influences sporadic CJD
• Octapeptide repeat number variations

Therapeutic Strategies

Current Approaches

No effective disease-modifying therapies exist for prion diseases. Strategies under investigation include [@Aguib2022][@Johnson2005][@Caughey2009]:

Challenges

• The blood-brain barrier limits drug delivery
• PrP^Sc exists in multiple strains with distinct properties
• Intervention must occur early in disease course
• Need for reliable biomarkers to guide treatment
• Heterogeneity of clinical presentations complicates diagnosis

Specific Prion Disease Types

Sporadic Creutzfeldt-Jakob Disease (sCJD)

sCJD represents approximately 85% of all human prion disease cases:

Epidemiology

• Incidence: 1-2 per million annually worldwide
• Typically presents in individuals 50-70 years of age
• Slight male predominance in some populations

• Rapidly progressive dementia
• Ataxia and cerebellar signs
• Myoclonus (especially startle-induced)
• Visual disturbances including cortical blindness
• Pyramidal and extrapyramidal signs
• Akinetic mutism in late stages

• MM1/MV1: Most common, rapid progression
• VV2: Cerebellar predominant, slower progression
• MM2: Longer disease duration

• 14-3-3 protein in cerebrospinal fluid
• Periodic sharp wave complexes on EEG
• MRI hyperintensities in cortex and basal ganglia
• Real-time quaking-induced conversion (RT-QuIC) positive

Variant Creutzfeldt-Jakob Disease (vCJD)

vCJD results from exposure to bovine spongiform encephalopathy (BSE):

Epidemiology

• Linked to consumption of BSE-contaminated beef
• First described in 1996 in the United Kingdom
• Approximately 230 cases worldwide

• Psychiatric symptoms at onset (depression, anxiety)
• Behavioral changes and personality alterations
• Sensory abnormalities including dysesthesia
• Ataxia developing later in disease course
• Progressive dementia
• Longer survival than sCJD (median 14-18 months)

• PrP amyloid plaques (florid plaques) throughout brain
• PrP deposition in lymphoid tissues
• Spongiform changes in basal ganglia and cerebellum

Fatal Familial Insomnia (FFI)

FFI represents a unique prion disease with predominant sleep dysfunction:

Genetic Basis

• Caused by PRNP mutation D178N with methionine at codon 129
• Autosomal dominant inheritance
• Incomplete penetrance depending on codon 129 genotype

• Progressive insomnia
• Autonomic dysfunction (hyperhidrosis, hypertension)
• Dysphagia and weight loss
• Cognitive decline in later stages
• Visual and auditory hallucinations

• Selective thalamic degeneration, especially dorsomedial nucleus
• Minimal spongiform change
• PrP deposition in thalamus and inferior olive

Gerstmann-Sträussler-Scheinker Syndrome (GSS)

GSS is a rare inherited prion disease:

Genetic Basis

• PRNP mutations including P102L, A117V, F198I, Q217R
• Autosomal dominant inheritance
• Variable age of onset (35-55 years typically)

• Progressive ataxia
• Dementia (later onset than ataxia)
• Pyramidal signs
• Extrapyramidal features in some subtypes
• Disease duration: 2-10 years

• PrP amyloid plaques throughout cerebellum and cerebral cortex
• Multicentric plaque formation
• Spongiform changes variable

Iatrogenic Prion Disease

Transmission through medical procedures includes:

Sources of Transmission

• Dura mater grafts (historical)
• Corneal transplants
• Human growth hormone (historical)
• Gonadotropin hormone
• Blood transfusion (rare cases)

• Similar to sCJD but longer incubation periods
• For growth hormone cases: 5-20 year incubation
• Typically rapid progression once symptomatic

Cellular and Molecular Mechanisms

PrP^Sc Conversion Mechanism

The conversion of PrP^C to PrP^Sc involves:

Template-Directed Conversion

• PrP^Sc serves as template for conversion of PrP^C
• Conformational information transfer through direct interaction
• Heterodimer formation as intermediate

• PrP^Sc aggregates form through seeded polymerization
• Lag phase followed by exponential growth
• Fibril elongation through addition of monomers

• Loss of α-helical content (from 40% to 20%)
• Increase in β-sheet structure (from 10% to 40%)
• Domain rearrangement in C-terminal region

PrP^Sc Strain Diversity

Prion strains represent different conformations:

Strain Characteristics

• Distinct physicochemical properties
• Different incubation periods in hosts
• Variable neuropathology
• Differential protease resistance patterns

• Different folding patterns of PrP^Sc
• Variations in aggregation state
• Distinct protofibril structures

Cellular Toxicity Pathways

PrP^Sc causes neurotoxicity through multiple mechanisms:

ER Stress

• Accumulation of misfolded proteins triggers unfolded protein response
• CHOP-mediated apoptosis
• Disruption of calcium homeostasis

• Mitochondrial dysfunction
• Increased reactive oxygen species
• Lipid peroxidation
• DNA damage

• Loss of synaptic proteins
• Impaired neurotransmitter release
• Disruption of synaptic plasticity
• Calcium dysregulation

• Microglial activation and inflammation
• Astrocyte reactivity
• Cytokine release
• Neuroinflammation amplification

PrP and Other Neurodegenerative Diseases

PrP in Parkinson's Disease

Connections between PrP and PD include:

• PrP expression in dopaminergic neurons
• Potential interaction with α-synuclein
• Role in metal homeostasis relevant to PD
• Possible common pathways in protein aggregation

PrP and Amyotrophic Lateral Sclerosis

ALS shares features with prion diseases:

• PrP deposition in some ALS cases
• Common mechanisms of protein aggregation
• Overlapping pathways of cellular stress

Metal Ion Homeostasis

PrP interacts with various metal ions:

Copper

• High affinity binding to octapeptide repeats
• Role in copper uptake and distribution
• Antioxidant function through SOD-like activity
• Dyshomeostasis in prion disease

• PrP affects iron metabolism
• Iron dysregulation in prion disease
• Possible role in oxidative stress

• PrP-zinc interactions
• Potential signaling functions

PrP as a Therapeutic Target

Immunotherapeutic Approaches

Active Immunization

• Vaccines targeting PrP^Sc
• Generation of anti-PrP antibodies
• Challenges: overcoming immune tolerance
• Clinical trials in animal models

• Administration of anti-PrP monoclonal antibodies
• Examples: 6D11, 8H4, Prioclone
• Delivery challenges across blood-brain barrier

Small Molecule Inhibitors

Polyanionic Compounds

• Sulfated glycans inhibit PrP conversion
• Pentosan polysulfate in clinical use
• Limitations: poor BBB penetration

• Doxycycline shows anti-prion activity
• Binding to PrP^Sc prevents aggregation
• Clinical trials ongoing

• Cu/Zn chelation reduces conversion
• Clioquinol trials in prion disease

Gene Silencing Approaches

Antisense Oligonucleotides

• Target PRNP mRNA
• Reduce PrP^C expression
• ASO trials in development
• Advantages: specificity, distribution

• siRNA targeting PRNP
• Viral vector delivery
• Challenges: efficient CNS delivery

Protein-Based Therapies

Dominant-Negative PrP

• Expression of mutant PrP that interferes with conversion
• Competitive inhibition of PrP^Sc formation
• Proof-of-concept in cell models

• Heat shock proteins in PrP metabolism
• Enhancement of PrP^C folding
• Targeting protein quality control

Diagnostic Biomarkers

Current Biomarkers

Cerebrospinal Fluid Markers

• 14-3-3 protein: sensitivity ~95%, specificity ~40%
• Tau protein: elevated in some cases
• Neurofilament light chain: promising marker

• Sensitivity: 80-90% for sCJD
• Specificity: >95%
• Detects PrP^Sc seeding activity
• Applied to CSF, olfactory epithelium, skin

Emerging Biomarkers

Blood-Based Markers

• PrP detection in plasma
• Exosome-associated PrP^Sc
• Sensitive detection methods in development

• PET ligands for PrP^Sc
• MRI advanced techniques
• Diffusion tensor imaging

Brain Atlas Resources

• Allen Human Brain Atlas: [PRNP expression search](https://human.brain-map.org/microarray/search/show?search_term=PRNP)
• Allen Mouse Brain Atlas: [Prnp search](https://mouse.brain-map.org/search/index.html?query=Prnp)
• BrainSpan Developmental Transcriptome: [PRNP developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=PRNP)

Clinical Trials and Emerging Therapies

Anti-Prion Compounds in Development:

• Polyanionic compounds that stabilize PrP^C
• Small molecules targeting PrP^Sc formation
• Natural products with anti-prion activity

• Active immunization with PrP antigens
• Passive monoclonal antibody administration
• Antibody fragments for better brain penetration
• CAR-T cell approaches for prion clearance

• PRNP knockdown using RNAi approaches
• CRISPR-based gene editing for correction
• PRNP expression modulation
• Viral vector-mediated delivery of anti-prion constructs

• Antibody plus small molecule combinations
• Gene therapy with pharmacological adjuncts
• Multi-target approaches for maximum effect

Protein Dynamics and Misfolding

Folding Pathways:

• PrP folding occurs in the endoplasmic reticulum
• Misfolding can occur at multiple stages
• Quality control mechanisms normally prevent accumulation
• Failure of quality control leads to disease

• Nucleation-dependent polymerization
• Formation of oligomeric intermediates
• Amyloid fibril assembly
• Strain variation through different conformations

• ER-associated degradation (ERAD)
• Autophagy-lysosome pathway
• Proteasome-mediated degradation
• Unfolded protein response activation

PrP in Prion Disease Subtypes

Sporadic CJD (sCJD):

• Most common form (~85% of cases)
• No known genetic or infectious cause
• Likely spontaneous PrP^Sc formation
• Variable clinical presentation based on PRNP genotype

• Acquired from BSE exposure
• Younger age of onset than sCJD
• Prominent psychiatric features
• Long incubation period

• Transmission through medical procedures
• corneal transplants, dura mater grafts
• Contaminated human growth hormone
• Blood transfusion transmission documented

• PRNP D178N mutation with methionine at codon 129
• Primary insomnia with autonomic dysfunction
• Selective thalamic degeneration
• Distinct clinical phenotype from CJD

PrP Structural Biology

X-ray Crystallography:

• Detailed structure of C-terminal domain
• Insight into helix-turn-helix arrangement
• Domain organization in the structured region

• Dynamics of N-terminal domain
• Flexible regions in physiological conditions
• Conformational changes upon misfolding

• Amyloid fibril structures
• Different prion strain conformations
• Polymorphic fibril architectures

PrP in Neurodevelopment

Developmental Expression:

• High expression during embryogenesis
• Peak levels in early postnatal period
• Sustained expression in adult brain
• Cell type-specific patterns

• Neuronal differentiation
• Synapse formation
• Myelination
• Astrocyte maturation

• Relatively mild phenotype in Prnp-/- mice
• Compensatory mechanisms exist
• Subtle neurological deficits in specific contexts

Research Methods

Biochemical Approaches:

• Western blotting for PrP detection
• ELISA for quantification
• Pulse-chase experiments for trafficking
• Proteomics for interaction mapping

• Cell culture models (neurons, astrocytes)
• Primary neuronal cultures
• Stem cell-derived neurons
• Live cell imaging

• Mouse models of prion disease
• Transgenic mice expressing mutant PRNP
• Knock-in models with human PRNP
• Zebrafish models for development

• X-ray crystallography
• NMR spectroscopy
• Cryo-electron microscopy
• Mass spectrometry

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Prion Diseases](/diseases/prion-diseases)
• [PRNP Gene](/genes/prnp)
• [Amyloid-beta Protein](/proteins/amyloid-beta)
• [Protein Misfolding in Neurodegeneration](/mechanisms/protein-misfolding-neurodegeneration)
• [Synaptic Dysfunction](/mechanisms/synaptic-failure-pathway)

External Links

• UniProt: [P04156 - PRNP](https://www.uniprot.org/uniprotkb/P04156)
• AlphaFold: [PrP Structure Prediction](https://alphafold.ebi.ac.uk/entry/P04156)
• OMIM: [176640 - PRNP](https://omim.org/entry/176640)
• GeneCards: [PRNP](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PRNP)
• PubMed: [Prion protein literature](https://pubmed.ncbi.nlm.nih.gov/?term=prion+protein+PRNP)
• Human Protein Atlas: [PRNP expression](https://www.proteinatlas.org/ENSG00000161133-PRNP)
• STRING Database: [PrP interaction network](https://string-db.org/)

Prion Disease Surveillance and Public Health

Global Surveillance Networks:

• National CJD surveillance systems
• WHO collaborative surveillance
• Rapid alert systems for new variants

• Cattle testing protocols
• Feed restrictions and controls
• Human exposure risk assessment

• Sterilization protocols for surgical equipment
• Blood donor screening
• Tissue transplantation safety

PrP and Copper Metabolism Connection

Copper Binding Properties:

• High affinity binding to octapeptide repeats
• Different affinity for Cu(I) and Cu(II)
• Multiple binding sites per PrP molecule

• PrP may function as copper receptor
• Facilitates copper uptake into cells
• Participates in cellular copper distribution

• Copper dyshomeostasis in prion disease
• Potential therapeutic targeting of copper pathways
• Interaction with other neurodegenerative processes

PrP and Zinc Metabolism

Zinc Binding:

• PrP can bind zinc ions
• Different binding site than copper
• Modulates PrP aggregation properties

• Important for synaptic function
• PrP may regulate zinc availability
• Implications for synaptic plasticity

PrP in Oligodendrocyte Function

Myelin Maintenance:

• PrP expressed in oligodendrocytes
• Important for myelin integrity
• Dysfunction may contribute to demyelination

• White matter changes in CJD
• Potential for therapeutic intervention
• Imaging biomarkers for progression

PrP in Astrocyte Function

Astrocyte Expression:

• PrP expressed in astrocytes
• Functions in astrocyte-neuron communication
• May influence neurovascular unit

• Astrocyte activation in prion disease
• Both protective and harmful roles
• Potential therapeutic target

PrP and Blood-Brain Barrier

BBB Regulation:

• PrP influences BBB development
• Maintains BBB integrity
• Dysfunction allows peripheral access

• Drug delivery challenges
• Strategies to improve brain penetration
• Engineering of therapeutic antibodies

Genetic Epidemiology

Population Studies:

• Allele frequency variations
• Founder mutations in specific populations
• Consanguinity effects on incidence

• 129 polymorphism effects
• Mutation-specific clinical presentations
• Modifier genes and modifiers

PrP in Veterinary Medicine

Animal Prion Diseases:

• Scrapie in sheep and goats
• BSE in cattle
• Chronic wasting disease in cervids
• Feline spongiform encephalopathy

• Species barrier studies
• Cross-species transmission
• Public health implications

Future Research Directions

Basic Science Priorities:

• Structural basis for strain variation
• Molecular mechanisms of neurotoxicity
• Early diagnostic markers

• Disease-modifying therapies
• Biomarkers for clinical trials
• Early intervention strategies

• Small molecule development
• Antibody therapeutics
• Gene therapy approaches
• Combination therapies

References